Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21
Phase 31

Trial Status

Completed1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT04499924Phase 2/3Completed
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
StudydirectorStart date: 2021-03-22

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

JoAl Mayor, PharmD, BCOP

Seagen Inc.

Moderately Similar
4 trials

Shared therapeutic areas:

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Worked with same sponsors:

Seagen Inc.
Collaborated on 1 trial
Similarity Score34%

Manish Shah, M.D.

Weill Medical College of Cornell University

Moderately Similar
4 trials

Shared therapeutic areas:

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score30%

Daniel Catenacci, MD

University of Chicago

Moderately Similar
4 trials

Shared therapeutic areas:

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score30%

jiafu ji, MD

Peking University Cancer Hospital & Institute

Related
7 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

Tannaz Armaghany, MD

Baylor College of Medicine

Related
4 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

yanqiao zhang, phD

Harbin Medical University Cancer Hosptital

Related
4 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

Jiafu Ji, M.D.

Peking University Cancer Hospital & Institute

Related
4 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

Ajay Goel, PhD

City of Hope Medical Center

Related
24 trials

Shared therapeutic areas:

Esophageal AdenocarcinomaGastric Adenocarcinoma
Similarity Score20%

Lin Shen, MD

Peking University Cancer Hospital & Institute

Related
20 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

lin shen, Professor

Peking University Cancer Hospital & Institute

Related
10 trials

Shared therapeutic areas:

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Similarity Score20%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT04499924Phase 2/3StudyDirector

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Completed

All 1 trials loaded